Drug Trial Radar · NCT01836705
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Last checked: Nov 21, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 2013
Primary completion
Nov 2013
Study completion May 2014
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors. Secondary Objectives: * To assess the effect of SAR302503 administered as 14-day repeated doses on heart rate (HR), QT, QTcB, and QTcN, PR and QRS compared to placebo. * To assess the clinical and laboratory safety of SAR302503 * To document the plasma concentrations of SAR302503 at the time of ECG investigation. * To explore the Pharmacokinetic/Pharmacodynamic relationship between SAR302503 concentration and QTcF * To explore antitumor activity
Conditions
- Neoplasm Malignant
Interventions
SAR302503 (TG101348)Drug
Pharmaceutical form:capsule Route of administration: oral
Placebo SAR302503Drug
Pharmaceutical form:capsule Route of administration: oral
PanolosetronDrug
Pharmaceutical form:solution Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- QTc Friderica (QTcF) parameterTime frame: 16 days
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number 840003
Los Angeles, California
Investigational Site Number 840007
Augusta, Georgia
Investigational Site Number 840002
Detroit, Michigan
Investigational Site Number 840001
St Louis, Missouri
Investigational Site Number 840004
Cincinnati, Ohio
Investigational Site Number 840005
Philadelphia, Pennsylvania
Investigational Site Number 840006
San Antonio, Texas
Investigational Site Number 840008
San Antonio, Texas
Investigational Site Number 056001
Brussels, Belgium
Investigational Site Number 056002
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.